Your browser doesn't support javascript.
loading
Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes.
Chung, Tony K H; Doran, Graeme; Cheung, Tak-Hong; Yim, So-Fan; Yu, Mei-Yung; Worley, Michael J; Elias, Kevin M; Thorner, Aaron R; Pedamallu, Chandra Sekhar; Ojesina, Akinyemi I; Lau, Kei-Man; Ducar, Matthew D; Wong, Raymond R Y; Wang, Vivian W; Nag, Anwesha; Wollison, Bruce M; Dalgarno, Audrey; Lee, Jacqueline H S; Yeung, Suet-Ying; Wong, Lo; Horowitz, Neil S; Davis, Michelle R; Leung, Shuk-On A; Mu, Yi; Mok, Samuel C; Chan, Paul K S; Lawrence, Michael S; Crum, Christopher P; Chiu, Rossa W K; Berkowitz, Ross S; Wong, Yick-Fu.
Afiliação
  • Chung TKH; The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
  • Doran G; Firefly Bioworks, Inc., Cambridge, MA 02139, USA.
  • Cheung TH; The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
  • Yim SF; The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
  • Yu MY; The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
  • Worley MJ; Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Elias KM; Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Thorner AR; Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Pedamallu CS; Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Ojesina AI; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Lau KM; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Ducar MD; The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
  • Wong RRY; Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Wang VW; The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
  • Nag A; Mayo Clinic, Rochester, MN 55902, USA.
  • Wollison BM; Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Dalgarno A; Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Lee JHS; Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
  • Yeung SY; The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
  • Wong L; The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
  • Horowitz NS; The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
  • Davis MR; Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Leung SA; Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Mu Y; Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Mok SC; Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Chan PKS; MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA.
  • Lawrence MS; The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
  • Crum CP; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Chiu RWK; Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Berkowitz RS; Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Wong YF; The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.
Cancers (Basel) ; 13(13)2021 Jun 28.
Article em En | MEDLINE | ID: mdl-34203201
ABSTRACT
Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient's circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women's cancer.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Hong Kong
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Hong Kong